GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scholar Rock Holding Corp (NAS:SRRK) » Definitions » Earnings Yield (Joel Greenblatt) %

Scholar Rock Holding (Scholar Rock Holding) Earnings Yield (Joel Greenblatt) % : -14.14% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Scholar Rock Holding Earnings Yield (Joel Greenblatt) %?

Scholar Rock Holding's Enterprise Value for the quarter that ended in Dec. 2023 was $1,210.29 Mil. Scholar Rock Holding's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-171.30 Mil. Scholar Rock Holding's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -14.14%.

The historical rank and industry rank for Scholar Rock Holding's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

SRRK' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -346.77   Med: -21.65   Max: 1085.69
Current: -19.49

During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Scholar Rock Holding was 1085.69%. The lowest was -346.77%. And the median was -21.65%.

SRRK's Earnings Yield (Joel Greenblatt) % is ranked worse than
54.3% of 1394 companies
in the Biotechnology industry
Industry Median: -15.455 vs SRRK: -19.49

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Scholar Rock Holding's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Scholar Rock Holding Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Scholar Rock Holding's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scholar Rock Holding Earnings Yield (Joel Greenblatt) % Chart

Scholar Rock Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial -22.68 -6.33 -18.59 -60.61 -14.14

Scholar Rock Holding Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.61 -80.65 -70.42 -67.11 -14.14

Competitive Comparison of Scholar Rock Holding's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Scholar Rock Holding's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scholar Rock Holding's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Scholar Rock Holding's Earnings Yield (Joel Greenblatt) % falls into.



Scholar Rock Holding Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Scholar Rock Holdings Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-171.295/1210.2946
=-14.15 %

Scholar Rock Holding's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-171.30 Mil.



Scholar Rock Holding  (NAS:SRRK) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Scholar Rock Holding Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Scholar Rock Holding's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Scholar Rock Holding (Scholar Rock Holding) Business Description

Industry
Traded in Other Exchanges
Address
301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is Apitegroma which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF?1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
Executives
Mo Qatanani officer: SVP and Head of Research 301 BINNEY STREET, 3RD FLOOR, C/O SCHOLAR ROCK HOLDING CORP, CAMBRIDGE MA 02142
Caryn Parlavecchio officer: CHRO SCHOLAR ROCK HOLDING CORPORATION, 301 BINNEY STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Junlin Ho officer: General Counsel 301 BINNEY STREET, CAMBRIDGE MA 02142
Edward H Myles director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Samsara Biocapital Gp, Llc 10 percent owner 251 CHURCHILL AVENUE, PALO ALTO CA 94301
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
Invus Public Equities, L.p. 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Tracey Sacco officer: Chief Commercial Officer 301 BINNEY STREET, 3RD FLOOR, C/O SCHOLAR ROCK HOLDING CORP, CAMBRIDGE MA 02142
Richard Brudnick director BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Jing L. Marantz officer: Chief Medical Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jay T. Backstrom officer: CEO-Elect SCHOLAR ROCK HOLDING CORPORATION, 301 BINNEY STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Amir Nashat director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Samsara Biocapital, L.p. 10 percent owner 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Artal Group S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal International S.c.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661